Abstract
To compare the associations between concomitant liraglutide use versus no liraglutide use and the risk of major adverse cardiovascular events (MACE) and all-cause mortality among patients receiving basal insulin (either insulin degludec [degludec] or insulin glargine 100 units/mL [glargine U100]) in the Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE). Patients with type 2 diabetes and high cardiovascular risk were randomized 1:1 to degludec or glargine U100. Hazard ratios for MACE/mortality were calculated using a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction. Sensitivity analyses were adjusted for baseline covariates including, but not limited to, age, sex, smoking and prior cardiovascular disease. At baseline, 436/7637 (5.7%) patients were treated with liraglutide; after baseline, 187/7637 (2.4%) started and 210/7637 (2.7%) stopped liraglutide. Mean liraglutide exposure from randomization was 530.2 days. Liraglutide use versus no liraglutide use was associated with significantly lower hazard rates for MACE [0.62 (0.41; 0.92)95%CI ] an...Continue Reading
References
Jun 1, 2012·Diabetes, Obesity & Metabolism·J J Holst, T Vilsbøll
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Apr 17, 2013·Diabetes Care·Elizabeth R SeaquistRobert Vigersky
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Jul 17, 2015·Diabetes, Obesity & Metabolism·A AhmannUNKNOWN NN2211-3917 Study Group
Sep 24, 2015·Journal of Hepatology·Matthew J ArmstrongJeremy W Tomlinson
Oct 30, 2015·BMJ : British Medical Journal·Marcus LindNils-Gunnar Pehrsson
Mar 5, 2016·JAMA : the Journal of the American Medical Association·Ildiko LingvayUNKNOWN DUAL V Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 7, 2016·American Heart Journal·Steven P MarsoJohn B Buse
Apr 23, 2017·Diabetes & Metabolism·B Vergès, B Charbonnel
Jun 13, 2017·The New England Journal of Medicine·Steven P MarsoUNKNOWN DEVOTE Study Group
Jul 20, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Virginia ValentineJay H Shubrook
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 28, 2018·Diabetes Care·Liana K BillingsEsteban Jodar
May 21, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Eveline BruinstroopP Sytze van Dam
Oct 7, 2018·Diabetes Care·Melanie J DaviesJohn B Buse
Feb 15, 2019·Diabetes, Obesity & Metabolism·Clifford J Bailey
Citations
Jul 10, 2019·Diabetes, Obesity & Metabolism·Cees J TackUNKNOWN LEADER Publication Committee on behalf of the LEADER Trial Investigators
Dec 25, 2019·BMC Cardiovascular Disorders·Chengcong ChenGuoqing Dong
Aug 7, 2019·Diabetes, Obesity & Metabolism·Eden MillerLiana K Billings
Jan 22, 2020·Drugs·Stewart HarrisTina Vilsbøll
Oct 26, 2021·The Cochrane Database of Systematic Reviews·Takayoshi KanieJoey Sw Kwong
Nov 3, 2020·Clinical Diabetes : a Publication of the American Diabetes Association·Joseph TibaldiJodi Strong
Jan 25, 2020·Clinical Diabetes : a Publication of the American Diabetes Association·Mark Warren, Donna Steel
Dec 16, 2021·Diabetes, Obesity & Metabolism·Kristin K ClemensSalimah Z Shariff